London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit

London's new listings volume hit a 28-year low in the first half of 2024, a grim milestone underscored by reports of AstraZeneca Plc's CEO considering a US listing. This decline is part of a broader trend where companies are seeking greater liquidity, with over $100 billion in London-listed firms having already moved or planning moves to New York. The ongoing exodus, coupled with insufficient IPOs and increasing take-privates, is intensifying pressure on London to reverse the shrinking of its historic trading venue.

Analysis

The London stock market is facing a severe structural crisis, with new listing volumes in the first half of the year falling to a 28-year low. This downturn is critically highlighted by the potential delisting of AstraZeneca Plc, a cornerstone of the FTSE 100, which is reportedly considering a primary listing in the US to access deeper liquidity pools. This is not an isolated incident but part of a significant trend, with Bloomberg data showing over $100 billion in market value from London-listed firms has either moved or is planning to move to New York. The market's decline is compounded by a lack of IPOs to replace a steady flow of companies being taken private, creating a negative feedback loop that shrinks the exchange. While the overall sentiment is strongly negative (-0.8) with a high market impact score (0.8), the slightly positive sentiment for AstraZeneca itself (AZN: 0.2) suggests investors believe a US listing could unlock greater value for the company, even as it damages the prestige and viability of the London venue.

Key Decisions for Investors

• Investors should reassess their exposure to UK-focused market indices and funds, as the persistent trend of delistings and low IPO activity signals potential for long-term underperformance and reduced market liquidity.
• For AstraZeneca (AZN) shareholders, a potential US relisting could act as a positive catalyst for the stock by unlocking a higher valuation and increasing its appeal to a larger investor base, though execution risk remains a key factor to monitor.
• Consider screening for other large-cap, internationally-focused UK companies that may be candidates for a US listing, as this trend presents both event-driven opportunities and a systemic risk to UK-centric portfolios.
• The capital flight from London may warrant a strategic shift in European allocations towards exchanges that are proving more successful at attracting and retaining major listings.